Please login to the form below

Vertex Pharma

This page shows the latest Vertex Pharma news and features for those working in and with pharma, biotech and healthcare.

Vertex gains FDA fast track designation for diabetes stem cell therapy

Vertex gained VX-880 from its previous acquisition of Semma Therapeutics for $950m in September 2019. ... This will help to protect the islet cells from immune rejection, Vertex said in a statement.

Latest news

Vertex’s triple combination CF therapy to become available on the NHS

NHS England has reached an agreement with Vertex for immediate access to the pharma company’s transformative triple combination therapy for cystic fibrosis (CF). ... eligible will be able to benefit from access to Vertex’s other CF drugs.
Vertex continues upward trajectory with French Orkambi deal

The American pharma giant reached an agreement with the English regulatory bodies in October, for access to Orkambi and Vertex’s other CF treatments Symkevi (tezacaftor-ivacaftor) and Kalydeco (ivacaftor). ... Vertex has also submitted the triple
Vertex reveals promising data from first CRISPR-treated patients

beta thalassemia,” said Jeffrey Leiden (pictured left), president and chief executive officer of Vertex. ... Vertex paid CRISPR Therapeutics $105m upfront in 2015, with up to $420m in milestone payments, to tap into its gene-editing expertise.
Vertex, NHS England and NICE finally reach agreement for Orkambi

to treat the underlying cause of their disease,” said Ludovic Fenaux (pictured right), senior vice president, Vertex International. ... We are pleased an agreement has been reached between NHS England and Vertex that brings these medicines to patients.
Vertex scores FDA approval for CF triple therapy Trikafta

The approval comes only a few months after Vertex filed the triple therapy with the FDA. ... Vertex has also submitted the triple therapy to the European Medicines Agency, with a decision expected in 2020.

More from news
Approximately 6 fully matching, plus 49 partially matching documents found.

Latest Intelligence

Health trust in a COVID-19 world – a unique opportunity for pharma

There were also some high-profile reimbursement stand-offs between pharma and the NHS (eg, Vertex/Orkambi). ... to the pharma industry, which is seen as being responsible for the high price of medicines).
The Cystic Fibrosis Buyers’ Club

This includes overriding pharma patents – something the group is advocating in relation to three drugs – Vertex’s cystic fibrosis treatment Orkambi, Pfizer’s breast cancer treatment Ibrance and Roche’s breast ... Meticulous preparations. The
Vertex: a vision of treating all CF patients worldwide draws closer

Its high prices are controversial, but Vertex also embodies the best of biopharma drug development. ... The failure of Proteostasis has led analysts to upgrade forecasts for Vertex’s own franchise.
The Orkambi blame game

The deadlock between pharma company Vertex and NHS England over cystic fibrosis drug Orkambi was played out in a parliamentary hearing in London on 7 March, when the company’s CEO ... NHS England accusing Vertex of being an“extreme outlier” and
2019: CRISPR and therapeutic gene editing comes of age

The green light came after a delay of around a year caused by manufacturing issues, which allowed another candidate from CRISPR Therapeutics and Vertex Pharma - CTX001 for the rare blood disease

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

Vertex poaches new finance chief from Ironwood Pharmaceuticals

Boston-based biotech company appoints Tom Graney. Vertex lured Tom Graney away from Ironwood Pharmaceuticals, appointing him as its new senior vice president and chief financial officer. ... Tom has the ideal blend of financial acumen, leadership skills,
BMS appoints three independent directors

Meanwhile, Matthew Emmens and Theodore Samuels also join the pharma firm's board of directors. ... Since beginning his pharmaceutical career 40 years ago, Emmens has served as president, chief executive officer and chairman of Vertex Pharma, chief

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Account Management: Competitive Salary Offered

Senior Content Editor - Biotechnology: Salary TBC

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Principal Medical Writer: Varies on experience

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

PMHub

Add my company

Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?: The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.: Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....